Fredrik Schjesvold is Head of Oslo Myeloma Center, in Oslo, Norway. He is head of the Norwegian myeloma association; president elect of the Nordic Myeloma Study Group and a member of the European Myeloma Network young board. He is national investigator of 36 clinical trials in multiple myeloma, and principal investigator for 4 academic trials. He is a co-author of ESMO and IMWG guidelines, as well as lead author of the Norwegian myeloma guidelines. He is peer reviewer of several international journals, and co-editor of the journal Hemato. He is an international expert on myeloma and has given talks in Europe, America and Asia.

Dr Fredrik Schjesvold has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Targovax, Amgen, BMS, Takeda, Sanofi, Menarini, Abbvie, Janssen, Oncopeptides, GSK & Regeneron